Gold Nanoparticles: New Routes Across Old Boundaries
Overview
Authors
Affiliations
In recent years, gold nanoparticles have emerged as unique non-invasive drug carriers for targeting drugs to their site of action. Their site specificity has helped in increasing drugs' efficacy at lower dose as well as reduction in their side effects. Moreover, their excellent optical properties and small size offer their utilization as diagnostic tools to diagnose tumors as well as other diseases. This review focuses on various approaches that have been used in last several years for preparation of gold nanoparticles, their characterization techniques and theranostic applications. Their toxicity related aspects are also highlighted. Gold nanoparticles are useful as theranostic agents, owing to their small size, biocompatible nature, size dependent physical, chemical and optical properties etc. However, the challenges associated with these nanoparticles such as scale up, cost, low drug payload, toxicity and stability have been the major impediments in their commercialization. The review looks into all these critical issues and identifies the possibilities to overcome these challenges for successful positioning of metallic nanoparticles in market.
Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer.
Wei X, Cao W, Wang S, Zhang Y, Gao Z, Wang S Int J Nanomedicine. 2025; 20:2623-2643.
PMID: 40061885 PMC: 11887507. DOI: 10.2147/IJN.S509409.
Nanoparticles as a novel key driver for the isolation and detection of circulating tumour cells.
Bashir S, Zia M, Shoukat M, Kaleem I, Bashir S Sci Rep. 2024; 14(1):22580.
PMID: 39343959 PMC: 11439955. DOI: 10.1038/s41598-024-67221-4.
Antimicrobial Activity of -Mediated Gold Nanoparticles against : A Metabolomic and Docking Study.
Azmy L, Al-Olayan E, Abdelhamid M, Zayed A, Gheda S, Youssif K Int J Mol Sci. 2024; 25(18).
PMID: 39337576 PMC: 11432420. DOI: 10.3390/ijms251810090.
Stability and biological response of PEGylated gold nanoparticles.
Nguyenova H, Kalbacova M, Dendisova M, Sikorova M, Jarolimkova J, Kolska Z Heliyon. 2024; 10(9):e30601.
PMID: 38742054 PMC: 11089375. DOI: 10.1016/j.heliyon.2024.e30601.
Trejo-Teniente I, Jaramillo-Loranca B, Vargas-Hernandez G, Villanueva-Ibanez M, Tovar-Jimenez X, Olvera-Venegas P Front Bioeng Biotechnol. 2024; 12:1378601.
PMID: 38737534 PMC: 11082400. DOI: 10.3389/fbioe.2024.1378601.